Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein

Cathrin Schnack1, Bastian Hengerer, Frank Gillardon

  • 1Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Research, Biberach an der Riss, Germany.

Proteomics
|May 21, 2008
PubMed

Insights

Cyclin-dependent kinase 5 (Cdk5) phosphorylates protein phosphatase 1, regulatory subunit 14A (PPP1R14A), revealing a new role in CNS development. This study also assessed Cdk5 inhibitor selectivity, aiding neuroprotection research.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biochemistry

Background:

  • Cyclin-dependent kinase 5 (Cdk5) is crucial for central nervous system (CNS) development and implicated in neurodegeneration.
  • Over 20 substrates of Cdk5 have been identified, but their cellular functions remain largely unknown.
  • High-throughput protein microarrays offer a method for parallel identification of kinase substrates.

Purpose of the Study:

  • To identify novel substrates of Cdk5/p25 using protein microarray technology.
  • To confirm the phosphorylation of identified substrates.
  • To characterize the selectivity of the Cdk5 inhibitor indolinone A.

Main Methods:

  • Utilized Protoarray protein microarrays to screen for Cdk5 substrates.
  • Employed secondary assays to validate phosphorylation events.
  • Applied Functional Kinome Arrays to assess inhibitor selectivity.

Main Results:

  • Identified protein phosphatase 1, regulatory subunit 14A (PPP1R14A) as a novel substrate of Cdk5/p25.
  • Confirmed PPP1R14A phosphorylation by Cdk5/p25.
  • Validated the selectivity of indolinone A, identifying two additional targeted kinases.

Conclusions:

  • The identification of PPP1R14A as a Cdk5 substrate may elucidate Cdk5's role in synaptic signaling.
  • Understanding indolinone A's targets deepens insights into its neuroprotective mechanisms.
  • Protein array techniques require careful interpretation due to potential false negatives from protein conformation issues.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...